|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 601 PENNSYLVANIA AVENUE, NW, SOUTH BUILDING |
Address2 | |
City | WASHINGTON |
State | DC |
Zip Code | 20004 |
Country | USA |
3. Principal place of business (if different than line 2)
City | |
State | |
Zip Code | |
Country | |
|
5. Senate ID# 1581-12
|
||||||||
|
6. House ID# 306290000
|
TYPE OF REPORT | 8. Year | 2009 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Julie Simon Miller, Senior Associate Counsel |
Date | 01/20/2010 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
H.R. 15, National Health Insurance Act (Dingell) single-payer health reform; H.R. 109, America's Affordable Health Care Act (Fortenberg) essential benefits plan, high risk pools; H.R. 193, AmeriCare Health Care Act (Stark) new government health program;
H.R. 544, Flexible Health Savings Act (Royce) FSA rollovers; H.R. 676, United States National Health Care Act (Conyers) single payer health reform; H.R. 1086, Help Efficient, Accessible, Low-cost, Timely Healthcare Act (Gingrey) medical liability reform; H.R. 1200, American Health Security Act (McDermott) single-payer health reform; H.R. 1468, Medical Justice Act (Burgess) medical liability reform; H.R. 1493, Quality Health Care Coalition Act (Paul) antitrust exemption for physicians; H.R. 1658, Veterans Healthcare Commitment Act (Tiahrt) third party billing by VA for service-connected disabilities; H.R. 2221, Data Accountability and Trust Act (Rush) data security; H.R. 2249, Health Care Price Transparency Promotion Act (Burgess) price transparency; H.R. 2502, Comparative Effectiveness Research Act (Schrader) comparative effectiveness research; H.R. 2520, Patients Choice Act (Ryan) comprehensive health reform; H.R. 2607: Small Business Health Coverage (Johnson) association health plans; H.R. 2668, Choice in Health Options Insures Care for Everyone Act (Murphy) government run health plan; H.R. 2847, Jobs for Main Street Act (Mollohan) extension of COBRA subsidies for the unemployed; H.R. 3002, PATIENTS Act (Boehner) comparative effectiveness research; H.R. 3200, Americas Affordable Health Choices Act (Dingell) coverage expansions, quality improvements, delivery system reforms, comparative effectiveness research, administrative simplification, health disparities, prevention and wellness, public health and workforce issues, fraud and abuse; H.R. 3288, Consolidated Appropriations Act (Olver) high risk pool funding, comparative effectiveness research, HHS programs; H.R. 3293, Labor, HHS, Education Appropriations Act (Obey/Harkin) high risk pool funding, comparative effectiveness research, HHS programs; H.R. 3326, Defense Appropriations Act (Murtha) extension of COBRA subsidies for the unemployed; H.R. 3400, Empowering Patients First Act (Price) premium subsidies, national marketplace, medical liability reforms, wellness, transparency, quality; H.R. 3468, Prevention and Wellness Programs (Castle) incentives for prevention and wellness; H.R. 3472, Premium Discounts for Healthy Behavior (Dahlkemper) premium discounts for healthy behavior; H.R. 3590, Patient Protection and Affordable Care Act (Reid) coverage expansions, quality improvements, delivery system reforms, cost containment, health information technology, comparative effectiveness research, administrative simplification, health disparities, prevention and wellness, public health and workforce issues, fraud and abuse; H.R. 3962, Americas Affordable Health Choices Act (Dingell) coverage expansions, quality improvements, delivery system reforms, cost containment, health information technology, comparative effectiveness research, administrative simplification, health disparities, prevention and wellness, public health and workforce issues, fraud and abuse; H.R. 4061, Cybersecurity Enhancement Act (Lipinski) privacy protections for health information technology; S. 45, Medical Care Access Protection Act (Ensign) medical liability reform; S. 139, Data Breach Notification Act (Feinstein) data security; S. 179, Health Information Technology Act (Stabenow) health information technology; S. 458, False Claims Act Clarification Act (Grassley) fraud and abuse; S. 698, State-Based Health Care Reform Act (Feingold) pilot projects for state-based health reforms; S. 703, American Health Security Act (Sanders) single-payer health reform; S. 913, Workforce Health Improvement Program Act (Cornyn) wellness incentives; S. 988, SIMPLE Cafeteria Plan Act (Snowe) cafeteria plans, flexible spending arrangements; S. 1099, Patients Choice Act (Coburn) comprehensive health reform; S. 1213, Patient-Centered Outcomes Research Act (Baucus) comparative effectiveness research; S. 1259, PATIENTS Act (Kyl) comparative effectiveness research; S. 1278, Consumers Health Care Act (Rockefeller) government run health plan; S. 1490, Personal Data Privacy and Security Act (Leahy) privacy, identity theft; S. 1679, Affordable Health Choices Act (Harkin) coverage expansions, quality improvements, delivery system reforms, health information technology, comparative effectiveness research, administrative simplification, health disparities, prevention and wellness, public health and workforce issues, fraud and abuse; S. 1734, Medical Liability Reform (Kyl) medical liability reform; S. 1796, Americas Healthy Future Act (Baucus) coverage expansions, quality improvements, delivery system reforms, health information technology, comparative effectiveness research, administrative simplification, health disparities, prevention and wellness, public health and workforce issues, fraud and abuse; S. 2730, COBRA Subsidy Extension and Enhancement Act (Brown) COBRA subsidies for the unemployed
HCR (Regulatory Issues):
HIPAA administrative simplification issues, including standards for privacy, security, and electronic transactions and code sets; HIPAA enforcement; FEHBP enrollment data clearinghouse initiative; issues relating to health insurance plan participation in FEHBP, including contract requirements related to interoperability of health information technology, community rating policies, and similarly sized subscriber group (SSSG) requirement; implementation of the health savings account provisions of the Medicare Act; issues related to Medicare Secondary Payer requirements; issues related to implementation of the National Health Information Infrastructure; issues relating to market consolidation; issues relating to quality improvement; issues related to potential priority research topics for the effective health care program; issues relating to the national health data stewardship; issues relating to hospital outpatient measurement and reporting; issues related to genetics and genetic nondiscrimination; issues relating to mental health parity; issues relating to data breach requirements; issues relating to "meaningful use" requirements for health information technology; and issues relating to Form 5500 reporting requirements.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Executive Office of the President (EOP), Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Labor - Dept of (DOL), Treasury - Dept of, Federal Trade Commission (FTC), Office of Personnel Management (OPM), Agency for Health Care Policy & Research, Internal Revenue Service (IRS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Gary |
Bacher |
|
|
|
Carmella |
Bocchino |
|
|
|
Elizabeth |
Brooks |
|
|
|
Jill |
Dowell |
|
|
|
Paul |
Eiting |
|
|
|
Behrends |
Foster |
|
|
|
Lindy |
Hinman |
|
|
|
Karen |
Ignagni |
|
|
|
Alethia |
Jackson |
|
|
|
Scott |
Keefer |
|
|
|
Jeff |
Lemieux |
|
|
|
Sue |
Rohan |
|
|
|
Candace |
Schaller |
|
|
|
Scott |
Styles |
|
|
|
Jeanette |
Thornton |
|
|
|
Kelly |
Vogel |
|
|
|
Thomas |
Wilder |
|
|
|
Marilyn |
Zigmund Luke |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
H.R. 684, Medicare Prescription Drug Savings and Choice Act (Berry) Part D reforms; H.R. 904, Medicaid Prescription Drug Rebate Equalization Act (Stupak) Medicaid drug costs; H.R. 1407, Medicare Part D Home and Community Services Copayment Equity Act (Doggett) Part D cost sharing;
H.R. 1670, Community Choice Act (Davis) Medicaid coverage; H.R. 1832, Medicare Prescription Drug Affordability Act (Wexler) Part D reforms; H.R. 2501, Medicare Cost Contract Extension and Refinement Act (Pomeroy) Medicare cost plans; H.R. 2686, Medicare Advantage Payments (Israel) Medicare Advantage benchmark adjustments; H.R. 2688, Empowered at Home Act (Pallone) home and community-based services under Medicaid; H.R. 2700, Prescription Coverage Now Act (Doggett) low-income assistance under Medicare Part D; H.R. 2718, MedPAC Reform Act (Cooper) implementation of Medicare payment policies; H.R. 2758, Medicare Specialty Care Improvement and Protection Act (Kind) Medicare Advantage special needs plans; H.R. 2847, Jobs for Main Street Act (Mollohan) Medicaid FMAP; H.R. 2860, Medicare Drug Savings Through Choice Act (Murphy) Part D reforms; H.R. 3152, Helping Seniors Choose their Medicare Drug Plan Act (Holt) Part D enrollment; H.R. 3200, Americas Affordable Health Choices Act (Dingell) Medicare Advantage, Part D, special needs plans, Medicare cost plans, Medicaid issues including MCO provider taxes and eligibility expansion, Medigap open enrollment, Medicare FFS payment reform; H.R. 3326, Defense Appropriations Act (Murtha) Medicare physician payment; H.R. 3418, Medicare Prescription Drug Cost Equalization Act (Ellsworth) Part D exceptions process; H.R. 3590, Patient Protection and Affordable Care Act (Reid) Medicare Advantage, Part D, special needs plans, Medicare cost plans, Medicaid issues including eligibility expansion and prescription drug pricing, Medigap changes, Medicare FFS payment reform; H.R. 3631, Medicare Premium Fairness Act (Titus) Part B premiums; H.R. 3962, Americas Affordable Health Choices Act (Dingell) Medicare Advantage, Part D, special needs plans, Medicare cost plans, Medicaid issues including MCO provider taxes, eligibility expansion and prescription drug pricing, Medigap changes, Medicare FFS payment reform; S. 75, Generics First Act (Kohl) Part D reforms; S. 266, Medicare Prescription Drug Gap Reduction Act (Nelson) Part D reforms; S. 330, Medicare Prescription Drug Savings and Choice Act (Durbin) Part D reforms; S. 534, Home and Community Services Copayment Equity Act (Nelson) Part D reforms; S. 547, Drug Rebate Equalization Act (Bingaman) Medicaid drug costs; S. 677, REPAIR Act (Ensign) means-testing Part D premiums; S. 683, Community Choice Act (Harkin) Medicaid coverage; S. 960, Medicare Early Access Act (Rockefeller) Medicare buy-in option; S. 1079, Medicare Cost Contract Extension and Refinement Act (Klobuchar) Medicare cost plans; S. 1307, Medicare Specialty Care Improvement and Protection Act (Feingold) Medicare Advantage special needs plans; S. 1380, MedPAC Reform Act (Rockefeller) implementation of Medicare payment policies; S. 1634, Medicare Prescription Drug Coverage Improvement Act (Rockefeller) government operated Part D plan, dual eligibles; S. 1669, Equal Access to Medicare Options Act (Kerry) guaranteed issue Medigap, Medicare Advantage enrollment; S. 1776, Medicare Physician Fairness Act (Stabenow) Medicare physician payment; S. 1796, Americas Healthy Future Act (Baucus) Medicare Advantage, Part D, special needs plans, Medicare cost plans, Medicaid issues including eligibility expansion and prescription drug rebates, Medigap restrictions, Medicare FFS payment reform
MMM (Regulatory Issues)
Ongoing implementation issues for the Medicare Advantage (MA) and Medicare Part D prescription drug programs, including risk adjustment methodology, data, and audit issues, bidding and payment issues (including MA rate assumptions, MA coding intensity, MA Secondary Payer issues, Part D reinsurance, Part D low income subsidies, and audits), application process, audits to evaluate compliance with MA and Part D program rules, benefit design rules, SSA and CMS premium withhold processing issues, enrollment rules, marketing materials review and approval, marketing activities, including conduct and compensation of brokers and agents and plan sponsor marketing staff, measurement and oversight of plan performance including Special Needs Plans (SNPs); quality measures, grievance and appeals processes, compliance/fraud and abuse training, and Medicare/Medicaid integration and contracting issues for Dual Eligible Special Needs Plans (SNPs); Federal preemption of State authority under MA and Part D programs, Part D prescription drug event data reporting, Part D formulary rules, Part D pharmacy access standards, and other operational issues; Medicare creditable drug coverage reporting requirements; implementation issues for the Medicare Retiree Drug Subsidy program; functionality of the Medicare Personal Plan Finder and Drug Plan Finder; National Medicare Education program; ongoing implementation issues for the Medicare cost plan program including enrollment, marketing materials review and approval and other operational issues, MA and Part D systems issues affecting enrollment and disenrollment processing and payment and other operational issues; Medicare demonstration program on performance-based payments for physician groups; physician quality reporting initiative; issues relating to Medicare coverage policy and national coverage decisions; Medicare clinical trials; Medicaid managed care regulations and policies, including the Medicaid managed care actuarial soundness standard, quality oversight, Medicaid and CHIP Payment and Access Commission (MACPAC), grievance and appeals processes, beneficiary information requirements, treatment of Medicaid health plan member hospital days in the upper payment limit calculation; policies affecting State Medicaid funding, including intergovernmental transfers (IGTs); coordination of benefits with state Medicaid programs; Medicaid prescription drug cost/rebate issues affecting Medicaid health plans; health plan-related Childrens Health Insurance Program (CHIP) issues, including eligibility and outreach issues; implementation of Medicaid changes made in Deficit Reduction Act of 2005, including documentation of citizenship requirements, state benefit flexibility options, and Medicaid managed care organization provider tax issues; standards for electronic prescribing; and health information technology standards and policies.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Executive Office of the President (EOP), Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Carmella |
Bocchino |
|
|
|
Jill |
Dowell |
|
|
|
Behrends |
Foster |
|
|
|
Karen |
Ignagni |
|
|
|
Alethia |
Jackson |
|
|
|
Jeff |
Lemieux |
|
|
|
Jennifer |
Rak |
|
|
|
Sue |
Rohan |
|
|
|
Candace |
Schaller |
|
|
|
Scott |
Styles |
|
|
|
Kelly |
Vogel |
|
|
|
Howard |
Weiss |
|
|
|
Thomas |
Wilder |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
H.R. 1204, Community Pharmacy Fairness Act (Weiner) antitrust exemption for pharmacies; H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act (Waxman) generic biologics; H.R. 1548, Pathway for Biosimilars Act (Eshoo) generic biologics (cont.)
H.R. 1706, Protecting Consumer Access to Generic Drugs Act (Rush) generic drugs; H.R. 3200, Americas Affordable Health Choices Act (Dingell) generic biologics; H.R. 3590, Patient Protection and Affordable Care Act (Reid) generic biologics; H.R. 3962, Americas Affordable Health Choices Act (Dingell) generic biologics, generic prescription drugs; S. 369, Preserve Access to Affordable Generics Act (Kohl) generic drugs; S. 726, Promoting Innovation and Access to Life-Saving Medicine Act (Schumer) generic biologics; S. 1630, Affordable Access to Prescription Medications Act (Rockefeller) prescription drug co-pays and formularies; S. 1679, Affordable Health Choices Act (Harkin) generic biologics
PHA (Regulatory):
Issues relating to long term safety and effectiveness of medical devices and drugs, including registries; issues relating to post-market surveillance of drugs and medical devices; and issues relating to access for investigational drugs.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Executive Office of the President (EOP), Food & Drug Administration (FDA), Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Office of Personnel Management (OPM), Drug Enforcement Administration (DEA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Carmella |
Bocchino |
|
|
|
Jill |
Dowell |
|
|
|
Behrends |
Foster |
|
|
|
Karen |
Ignagni |
|
|
|
Alethia |
Jackson |
|
|
|
Candace |
Schaller |
|
|
|
Scott |
Styles |
|
|
|
Kelly |
Vogel |
|
|
|
Howard |
Weiss |
|
|
|
Thomas |
Wilder |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code INS
16. Specific lobbying issues
H.R. 323, Comprehensive Insurance Coverage of Childhood Immunization Act (Green) immunization coverage mandate; H.R. 584, Menopausal Hormone Replacement Therapies and Alternative Treatments and Fairness Act (Lee) coverage mandate for hormone replacement therapy (cont.)
H.R. 697, Family Building Act (Weiner) coverage mandate for infertility treatments; H.R. 716, Access to Cancer Clinical Trials Act (Israel) clinical trials coverage mandate; H.R. 850, Small Business CHOICE Act (Velazquez) small employer health options; H.R. 859, Small Business CHOICE Act (Velazquez) small employer health options; H.R. 995, Mammogram and MRI Availability Act (Nadler) coverage mandate for mammograms; H.R. 1085, Health Insurance Coverage Protection Act (Eshoo) lifetime benefit limits; H.R. 1092, No Discrimination in Health Insurance Act (Kagen) preexisting condition exclusions, affiliation periods, uniform premiums; H.R. 1253, Health Insurance Restrictions and Limitations Clarification Act (Burgess) disclosure of coverage exclusions; H.R. 1321, Healthy Americans Act (Eshoo) comprehensive health reform; H.R. 1330, Colorectal Cancer Screening and Detection Coverage Act (Boren) coverage mandate for cancer screening; H.R. 1339, Children's Access to Reconstructive Evaluation & Surgery Act (McCarthy) coverage mandate for treatment of a child's congenital or developmental deformity; H.R. 1558, Preexisting Condition Patient Protection Act (Courtney) preexisting condition exclusions; H.R. 1583, Insurance Industry Competition Act (DeFazio) McCarran Ferguson reforms; H.R. 1619, Children's Health Protection Act (Schwartz) preexisting condition exclusions for children; H.R. 1691, Breast Cancer Patient Protection Act (DeLauro) rescissions, hospital stays for breast cancer patients; H.R. 1721, CLASS Act (Pallone) national LTC program; H.R. 1880, National Insurance Consumer Protection Act (Bean) regulatory reform; H.R. 2360, SHOP Act (Kind) small employer health options; H.R. 2402, Woman's Health Insurance Fairness Act (Neal) gender rating for health insurance; H.R. 2413, Autism Treatment Acceleration Act (Doyle) coverage for autism spectrum disorders; H.R. 2427, Informed Consumer Choices in Health Care Act (DeLauro) federal standards for health insurance, consumer information; H.R. 2457, Right to a Second Medical Opinion Act (Davis) coverage of second opinions; H.R. 2609, Insurance Information Act (Kanjorski) Federal Office of Insurance Information; H.R. 2635, Gender Equity in Health Premiums Act (Sanchez) gender rating for health insurance; H.R. 2833, Medical Loss Ratios (Ellison) medical loss ratios; H.R. 2940, Women's Obstetrician and Gynecologist Medical Access Now Act (Davis) direct access to ob/gyns; H.R. 3200, Americas Affordable Health Choices Act (Dingell) government-run health plan, health insurance exchange, regulatory reform, health choices commissioner, insurance market reforms, individual coverage requirement, benefit packages, CLASS Act, medical loss ratios, premium assistance; H.R. 3217, Health Care Choice Act (Shadegg) national marketplace; H.R. 3584, Health Care Consumer Protection Act (Forbes) reinstatement of coverage upon payment of overdue premiums; H.R. 3590, Patient Protection and Affordable Care Act (Reid) government-run health plan, health insurance cooperatives, multi-state plans, insurance market reforms, health insurance exchanges, benefit packages, medical loss ratios, CLASS Act, regulatory reform, individual coverage requirement, premium assistance, federal rate review process, health care choice compacts, appeals procedures, disclosure requirements, high risk pool program, McCarran-Ferguson Act; H.R. 3596, Health Insurance Industry Antitrust Enforcement Act (Conyers) changes to McCarran-Ferguson Act; H.R.3681, Fairness in Health Insurance Act (cont.)
H.R. 3961, Medicare Physician Payment Reform Act (Dingell) Medicare physician payment; H.R. 3962, Americas Affordable Health Choices Act (Dingell) government-run health plan, health insurance exchange, regulatory reform, health choices commissioner, insurance market reforms, individual coverage requirement, benefit packages, CLASS Act, medical loss ratios, premium assistance, federal rate review process, health care choice compacts, high risk pool program, McCarran-Ferguson Act; H.R. 4078, Long-Term Care Insurance Disclosure Act (Perriello) model disclosure form for long-term care insurance; S. 79, Healthy Businesses, Healthy Workers Reinsurance Act (Kerry) reinsurance; S. 93, Small Business Empowerment Act (Brown) small employer health options; S. 391, Healthy Americans Act (Wyden) comprehensive health reform; S. 442, Health Insurance Coverage Protection Act (Dorgan) lifetime benefit limits; S. 488, Access to Cancer Clinical Trials Act (Brown) clinical trials coverage mandate; S. 623, Pre-existing Condition Patient Protection Act (Rockefeller) preexisting condition exclusions; S. 643, Children's Health Protection Act (Lautenberg) preexisting condition exclusions for children; S. 688, Breast Cancer Patient Protection Act (Snowe) rescissions, hospital stays for breast cancer patients; S. 697, CLASS Act (Kennedy) national LTC program; S. 819, Autism Treatment Acceleration Act (Durbin) coverage for autism spectrum disorders; S. 969, Women's Health Insurance Fairness Act (Kerry) gender rating for health insurance; S. 979, SHOP Act (Durbin) small employer health options; S. 1050, Informed Consumer Choices in Health Care Act (Rockefeller) federal standards for health insurance, consumer information; S. 1149, Annual and Lifetime Health Care Limit Elimination Act (Rockefeller) annual and lifetime coverage limits; S. 1177, Confidence in Long-Term Care Insurance Act (Kohl) LTC consumer protections; S. 1235, Children's Access to Reconstructive Evaluation & Surgery Act (Landrieu) coverage mandate for treatment of a child's congenital or developmental deformity; S. 1258, Family Building Act (Gillibrand) coverage mandate for infertility treatments; S. 1459, Health Care Choice Act (DeMint) national marketplace; S. 1626, Long Term Care Insurance Integrity Act (Klobuchar) third party review of LTCI disputed claims; S. 1636, Long-Term Care Insurance Consumer Right-to-Know Act (Klobuchar) model disclosure forms for LTC insurance; S. 1679, Affordable Health Choices Act (Harkin) government-run health plan, insurance market reforms, health benefit gateways, benefit packages, medical loss ratios, CLASS Act, regulatory reform, individual coverage requirement, premium assistance; S. 1681, Health Insurance Industry Antitrust Enforcement Act (Leahy) changes to McCarran-Ferguson Act; S. 1730, Fairness in Health Insurance Act (Franken) medical loss ratios; S. 1796, Americas Healthy Future Act (Baucus) government-run health plan, health insurance cooperatives, health insurance exchange, insurance market reforms, individual coverage requirement, benefit packages, premium assistance, medical loss ratios, regulatory reform
INS (Regulatory)
Insurance regulatory reform; issues related to the coordination of private and public disability income benefits; disability risk management; issues relating to the coordination of benefits between private health insurance plans and Medicaid; Medigap claims processing and crossover fees; implementation of Medigap standardized plan offerings; Medigap carrier recoveries related to CMS fraud and abuse enforcement activities, and issues related to Medigap educational materials; implementation of the Mental Health Parity Act requirements; issues related to COBRA subsidy requirements, and issues related to genetic nondiscrimination.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Executive Office of the President (EOP), Health & Human Services - Dept of (HHS), Labor - Dept of (DOL), Treasury - Dept of, Social Security Administration (SSA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Gary |
Bacher |
|
|
|
Carmella |
Bocchino |
|
|
|
Elizabeth |
Brooks |
|
|
|
Susan |
Coronel |
|
|
|
Jill |
Dowell |
|
|
|
Paul |
Eiting |
|
|
|
Behrends |
Foster |
|
|
|
Lindy |
Hinman |
|
|
|
Karen |
Ignagni |
|
|
|
Alethia |
Jackson |
|
|
|
Scott |
Keefer |
|
|
|
Jeff |
Lemieux |
|
|
|
Sue |
Rohan |
|
|
|
Candace |
Schaller |
|
|
|
Scott |
Styles |
|
|
|
Jeanette |
Thornton |
|
|
|
Kelly |
Vogel |
|
|
|
Thomas |
Wilder |
|
|
|
Marilyn |
Zigmund Luke |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
H.R. 897, Long-Term Care and Retirement Security Act (Putnam) tax incentives for LTC insurance; H.R. 1891, Sunset of Life Protection Act (Alexander) tax incentives for LTC insurance (cont.)
H.R. 2096, Long-Term Care Affordability and Security Act (Pomeroy) tax incentives for LTC insurance; H.R. 2974: HSAs for Veterans (Campbell) HSA contributions by veterans; H.R. 3478, Patient-Controlled Healthcare Protection Act (Gohmert) HSA improvements, transparency; H.R. 3490, Wellness Programs (Johnson) tax incentives for employer-sponsored wellness programs; H.R. 3508, Healthy Savings Act (Paulsen) HSA improvements; H.R. 3590, Patient Protection and Affordable Care Act (Reid) premium tax, high-value health plan tax, LTC insurance in cafeteria plans, FSA limits, tax exclusion for FSAs and HRAs, health savings accounts, tax deduction for itemized medical expenses; H.R. 3610, Health Savings and Affordability Act (Austria) health insurance tax deduction, HSAs; H.R. 3962, Americas Affordable Health Choices Act (Dingell) FSA limits, health savings accounts, eligibility of OTC drugs as tax-free expense; H.R. 3971, Health Savings Account Expansion Act (Flake) HSA improvements; S. 94, Long-Term Care Family Accessibility Act (Vitter) tax incentives for LTC insurance; S. 702, Long-Term Care Affordability and Security Act (Grassley) tax incentives for LTC insurance; S. 1679, Affordable Health Choices Act (Harkin) LTC insurance in cafeteria plans; S. 1796, Americas Healthy Future Act (Baucus) high-cost health plan tax, industry tax, LTC insurance in cafeteria plans, FSA limits, employer tax exclusion, tax exclusion for FSAs and HRAs, health savings accounts, tax deduction for itemized medical expenses
TAX (Regulatory)
Issues relating to Health Savings Accounts; issues related to COBRA subsidy requirements; and issues relating to withholding of government contract payments.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Executive Office of the President (EOP)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Susan |
Coronel |
|
|
|
Behrends |
Foster |
|
|
|
Karen |
Ignagni |
|
|
|
Alethia |
Jackson |
|
|
|
Scott |
Keefer |
|
|
|
Scott |
Styles |
|
|
|
Kelly |
Vogel |
|
|
|
Thomas |
Wilder |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address | |
||||||
City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
5 |
|
||||||
2 |
|
6 |
|
||||||
3 |
|
7 |
|
||||||
4 |
|
8 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address: http://www.ahip.org/content/default.aspx?bc=31|42|54
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 3 | 5 |
2 | 4 | 6 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 5 | 9 |
2 | 6 | 10 |
3 | 7 | 11 |
4 | 8 | 12 |